Literature DB >> 17345045

Clinical-diffusion mismatch defined by NIHSS and ASPECTS in non-lacunar anterior circulation infarction.

H Tei1, S Uchiyama, T Usui.   

Abstract

OBJECTIVES: Instead of the mismatch in MRI between the perfusion-weighted imaging (PWI) lesion and the smaller diffusion-weighted imaging (DWI) lesion (PWI-DWI mismatch), clinical-DWI mismatch (CDM) has been proposed as a new diagnostic marker of brain tissue at risk of infarction in acute ischemic stroke. The Alberta Stroke Program Early CT Score (ASPECTS) has recently been applied to detect early ischemic change of acute ischemic stroke. The present study applies the CDM concept to DWI data and investigated the utility of the CDM defined by the NIH Stroke Scale (NIHSS) and ASPECTS in patients with non-lacunar anterior circulation infarction.
METHODS: Eighty-seven patients with first ever ischemic stroke within 24 hours of onset with symptoms of non-lacunar anterior circulation infarction with the NIHSS score>or=8 were enrolled. Initial lesion extent was measured by the ASPECTS on DWI within 24 hours, and initial neurological score was measured by the NIHSS. As NIHSS>or=8 has been suggested as a clinical indicator of a large volume of ischemic brain tissue, and the majority of patients with non-lacunar anterior infarction with score of NIHSS<8 had lesions with ASPECTS>or=8 on DWI, so CDM was defined as NIHSS>or=8 and DWI-ASPECTS 8>or=. We divided patients into matched and mismatched patient groups, and compared them with respect to background characteristics, neurological findings, laboratory data, radiological findings and outcome.
RESULTS: There were 35 CDM-positive patients (P group, 40.2%) and 52 CDM-negative patients (N group , 59.8%). P group patients had a higher risk of early neurological deterioration (END) than N group patients (37.1% vs 13.5%, p<0.05), which were always accompanied by lesion growth defined by 2 or more points decrease on ASPECTS (36 to 72 hours after onset on CT). The NIHSS at entry were significantly lower in the P group, but there was no difference in the outcome at three months measured by the modified Rankin Scale. However, CDM was not an independent predictor of END by multiple logistic regression analysis.
CONCLUSIONS: Patients with CDM had high rate of early neurological deterioration and lesion growth. CDM defined as NIHSS>or=8 and DWI-ASPECTS>or=8 can be another marker for detecting patients with tissue at risk of infarction, but more work is needed to clarify whether this CDM method is useful in acute stroke management.

Entities:  

Mesh:

Year:  2007        PMID: 17345045     DOI: 10.1007/s00415-006-0368-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  2000-12       Impact factor: 7.914

2.  "Clinical-CT mismatch" and the response to systemic thrombolytic therapy in acute ischemic stroke.

Authors:  David M Kent; Michael D Hill; Robin Ruthazer; Shelagh B Coutts; Andrew M Demchuk; Imanuel Dzialowski; Olaf Wunderlich; Rudiger von Kummer
Journal:  Stroke       Date:  2005-07-07       Impact factor: 7.914

3.  Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials.

Authors:  T J DeGraba; J M Hallenbeck; K D Pettigrew; A J Dutka; B J Kelly
Journal:  Stroke       Date:  1999-06       Impact factor: 7.914

4.  Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study.

Authors:  P L Kolominsky-Rabas; M Weber; O Gefeller; B Neundoerfer; P U Heuschmann
Journal:  Stroke       Date:  2001-12-01       Impact factor: 7.914

5.  Deteriorating ischemic stroke in 4 clinical categories classified by the Oxfordshire Community Stroke Project.

Authors:  H Tei; S Uchiyama; K Ohara; M Kobayashi; Y Uchiyama; M Fukuzawa
Journal:  Stroke       Date:  2000-09       Impact factor: 7.914

6.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Authors:  Werner Hacke; Greg Albers; Yasir Al-Rawi; Julien Bogousslavsky; Antonio Davalos; Michael Eliasziw; Michael Fischer; Anthony Furlan; Markku Kaste; Kennedy R Lees; Mariola Soehngen; Steven Warach
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

7.  Clinical-diffusion mismatch predicts the putative penumbra with high specificity.

Authors:  Jane Prosser; Ken Butcher; Louise Allport; Mark Parsons; Lachlan MacGregor; Patricia Desmond; Brian Tress; Stephen Davis
Journal:  Stroke       Date:  2005-07-14       Impact factor: 7.914

8.  Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging.

Authors:  P A Barber; M D Hill; M Eliasziw; A M Demchuk; J H W Pexman; M E Hudon; A Tomanek; R Frayne; A M Buchan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

9.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

10.  Change in perfusion in acute nondominant hemisphere stroke may be better estimated by tests of hemispatial neglect than by the National Institutes of Health Stroke Scale.

Authors:  Argye E Hillis; Robert J Wityk; Peter B Barker; John A Ulatowski; Michael A Jacobs
Journal:  Stroke       Date:  2003-09-04       Impact factor: 7.914

View more
  12 in total

1.  The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent.

Authors:  Bruce C V Campbell; Archana Purushotham; Soren Christensen; Patricia M Desmond; Yoshinari Nagakane; Mark W Parsons; Maarten G Lansberg; Michael Mlynash; Matus Straka; Deidre A De Silva; Jean-Marc Olivot; Roland Bammer; Gregory W Albers; Geoffrey A Donnan; Stephen M Davis
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-20       Impact factor: 6.200

2.  Clinical stroke penumbra: use of National Institutes of Health stroke scale as a surrogate for CT perfusion in patient triage for intra-arterial middle cerebral artery stroke therapy.

Authors:  J L Boxerman; M V Jayaraman; W A Mehan; J M Rogg; R A Haas
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-24       Impact factor: 3.825

3.  Effect of Collaterals on Clinical Presentation, Baseline Imaging, Complications, and Outcome in Acute Stroke.

Authors:  E M Fanou; J Knight; R I Aviv; S-P Hojjat; S P Symons; L Zhang; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-15       Impact factor: 3.825

4.  Magnetic resonance diffusion-perfusion mismatch in acute ischemic stroke: An update.

Authors:  Feng Chen; Yi-Cheng Ni
Journal:  World J Radiol       Date:  2012-03-28

5.  Diffusion-weighted ASPECTS as an independent marker for predicting functional outcome.

Authors:  Hideaki Tei; Sinichiro Uchiyama; Toru Usui; Kuniko Ohara
Journal:  J Neurol       Date:  2010-10-19       Impact factor: 4.849

6.  Predicting stroke evolution: comparison of susceptibility-weighted MR imaging with MR perfusion.

Authors:  Hung-Wen Kao; Fong Y Tsai; Anton N Hasso
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

7.  Posterior circulation ASPECTS on diffusion-weighted MRI can be a powerful marker for predicting functional outcome.

Authors:  Hideaki Tei; Shinichiro Uchiyama; Toru Usui; Kuniko Ohara
Journal:  J Neurol       Date:  2009-11-27       Impact factor: 4.849

8.  ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes.

Authors:  J R Sims; L Rezai Gharai; P W Schaefer; M Vangel; E S Rosenthal; M H Lev; L H Schwamm
Journal:  Neurology       Date:  2009-06-16       Impact factor: 9.910

9.  Late endovascular revascularization in acute ischemic stroke based on clinical-diffusion mismatch.

Authors:  N Janjua; A El-Gengaihy; J Pile-Spellman; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-04       Impact factor: 3.825

10.  Interleukin-10 facilitates the selection of patients for systemic thrombolysis.

Authors:  Manuel Rodríguez-Yáñez; Mar Castellanos; Tomás Sobrino; David Brea; Pedro Ramos-Cabrer; Salvador Pedraza; José A Castiñeiras; Joaquín Serena; Antonio Dávalos; José Castillo; Miguel Blanco
Journal:  BMC Neurol       Date:  2013-06-17       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.